Roche’s Tecentriq (atezolizumab) + CT Receive NMPA’s Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

 Roche’s Tecentriq (atezolizumab) + CT Receive NMPA’s Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

Roche’s Tecentriq (atezolizumab) + CT Receive NMPA’s Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

Shots:

  • The NMPA’s approval is based on P-III IMpower133 study assessing Tecentriq + CT vs PBO + CT as monothx. in 403 CT naïve patients in a ratio (1:1) with ES-SCLC
  • The P-III IMpower study results: OS (12.3 vs 10.3 mos.); mPFS (5.2 vs 4.3 mos.); follow up analysis @18mos. OS rate (34% vs 21%); safety profile is consistent with the previous profile
  • Tecentriq is a mAb targeting PD-L1, blocking its interaction with both PD-1 and B7.1 receptors.  In Jan’2020, NMPA has accepted sBLA for Tecentriq + Avastin (bevacizumab) for unresectable HCC, prior not treated with systemic therapy

Click here ­to­ read full press release/ article | Ref: Roche | Image: StraitTimes

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post